Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemo-immunotherapy for unresectable bronchogenic carcinoma.

G P Sarna, B B Lowitz, C M Haskell

    Cancer Treatment Reports
    |May 1, 1978
    PubMed
    Summary

    This study found that MOCA chemotherapy offers modest benefits for bronchogenic carcinoma, especially small cell types. Immunotherapy did not improve outcomes and C. parvum caused significant side effects.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Oncogenes and Anti-oncogenes in the Evolution of Human Leukemia/Lymphoma.

    Leukemia & lymphoma·2016
    Same author

    Phagocytosis and synthesis of ribonucleic acid in human granulocytes.

    Nature·2010
    Same author

    The femoral head/neck offset and hip resurfacing.

    The Journal of bone and joint surgery. British volume·2007
    Same author

    Polyethylene wear characteristics in vivo and in a knee stimulator.

    Journal of biomedical materials research·2002
    Same author

    Quality of life assessment in elite collegiate athletes.

    The American journal of sports medicine·2001
    Same author

    Survivorship analysis of cementless total hip arthroplasty in younger patients.

    The Journal of bone and joint surgery. American volume·2001

    Area of Science:

    • Oncology
    • Immunotherapy
    • Chemotherapy

    Background:

    • Bronchogenic carcinoma presents significant treatment challenges.
    • Combination chemotherapy regimens are explored to improve patient outcomes.

    Purpose of the Study:

    • To evaluate the efficacy of MOCA chemotherapy combined with immunotherapy (bacillus Calmette-Guérin or Corynebacterium parvum) in patients with metastatic or unresectable bronchogenic carcinoma.
    • To assess the impact of immunotherapy on response rates, survival, and chemotherapy tolerance.

    Main Methods:

    • Seventy-nine patients with bronchogenic carcinoma were treated with MOCA (methotrexate, Oncovin, cyclophosphamide, adriamycin).
    • Patients were randomized to receive MOCA alone, MOCA plus bacillus Calmette-Guérin, or MOCA plus Corynebacterium parvum.
    • Response rates, survival times, and adverse events were analyzed.

    Main Results:

    • The MOCA regimen showed a 68% response rate and 42-week median survival in small cell carcinoma, versus 18% and 29 weeks in other types.
    • Immunotherapy did not enhance response, delay progression, or improve hematopoietic tolerance.
    • Corynebacterium parvum immunotherapy was associated with significant morbidity and poor tolerance.

    Conclusions:

    • MOCA chemotherapy provides modest benefit for bronchogenic carcinoma, particularly small cell subtypes.
    • Current immunotherapy approaches do not improve outcomes in this setting.
    • The role of immunotherapy in bronchogenic carcinoma treatment remains unproven.

    Related Experiment Videos